key: cord-0984199-p5jma9b7
authors: Blaszczyk, Amie Taggart; Sandlin, Katherine; Mirza, Sumeen; Hernandez, Lilibeth; Bader, Hiba; Hall, Ronald G.
title: Potential for Drug Interactions and Polypharmacy from Treatment of COVID-19 in Long-term Care
date: 2022-04-06
journal: J Am Med Dir Assoc
DOI: 10.1016/j.jamda.2022.03.016
sha: ce14cbe76ca5d04f4171845c4aa40857b98da519
doc_id: 984199
cord_uid: p5jma9b7

Drug-drug interactions and polypharmacy are common as a result of COVID-19 therapies.

The COVID-19 pandemic has brought to public attention significant vulnerabilities of 2 older adults living in long-term care (LTC). 1-2 This is due not only to the direct risk of COVID-19 3 and its potential complications, but also the potential for inappropriate polypharmacy. 3 Acute 4 illnesses, of all types, commonly add medications to the profile and therefore increase the threat 5 of drug-drug interactions (DDI) and polypharmacy. Prescribers often fail to think of these issues 6 when in the midst of treating an acute problem. Residents in LTC are at increased risk of 7 medication related errors, with approximately 800,000 preventable medication related errors 8

occurring each year in this care setting. 4 Bundles of medications ("COVID cocktails") 9

prescribed to treat COVID-19 can include antibiotics, anticoagulants, systemic corticosteroids, 10 inhaled therapies, and nutritional supplements. Some of these therapies have evidence of 11 benefit in COVID-19, while many do not. 6 COVID cocktails can increase risk of medication 12 errors, drug interactions and pill burden. Risk can be longer term if medications for COVID-19 13 are not reviewed or discontinued after the acute illness resolves. Cocktails and other therapies 14 for acute illness have the potential for serious consequences, with state survey tag F757 among 15 them. 7 16

We sought to evaluate the impact of COVID-19 cocktails on polypharmacy, preventable 17 medication-related problems, such as drug-drug and drug-disease interactions, and persistence medications at +/-30 days from COVID diagnosis date were counted to assess if medication 25 regimens were permanently increased after COVID resolved. The date of COVID-19 diagnosis 26 was considered day zero. Descriptive statistics characterized the data. 27

There were 759 individuals (51.4% women) diagnosed with COVID-19 during the 6 29 month window with data available for 751 residents. Baseline characteristics included an 30 average age of 75.5 ± 12.6, with 17.7% (n=133) younger than 65-years-old and 27.3% (n=204) 31 older than 85-years-old. 32

Almost half (n=324, 43%) diagnosed with COVID had at least one medication initiated. In 33 this medication-added cohort, the average number of medications added was 2.62 ± 1.5 and 34 median number added was 2 (range 1 -7). Antibiotics (21.8%; n=164) and corticosteroids 35 which is consistent with reviews in community and hospital settings. 8,9 Post-hoc reflection noted 56 several anticoagulants started on the day of COVID diagnosis had new indications (e.g. 57 "anticoagulation") at 30 days, potentially making discontinuation difficult. 58

We recognize several limitations. We were unable to determine efficacy or safety 59 outcomes from these medication regimens and we limited the scope of our evaluation to ICD-10 60 coding, thus we were unable to characterize patients prescribed medication cocktails for 61 COVID-19 prophylaxis. This is a common occurrence from our own clinical experience in LTC. 62

Our data were pulled from LTC facilities within a single state (Texas), potentially limiting 63 generalizability. However, our results are consistent with other analyses. 8-10 64 especially when multiple medications are added all at once, and is a risk factor for adverse 66 outcomes in those with COVID-19. 11 However, this is not simply a "COVID issue" and occurs 67 with many acute illnesses in LTC. Thankfully, opportunities exist to mitigate the issues 

The New York Times. One-Third of U.S. Coronavirus Deaths Are Linked to Nursing

The double burden of the COVID-19 96 pandemic and polypharmacy on the geriatric population -public health implications

Preventing medication errors in long-99 term care: results and evaluation of a large scale web-based error reporting system

Trends in Prescribing of

Antibiotics and Drugs Investigated for Coronavirus Disease 2019 (COVID-19) Treatment

US Nursing Home Residents During the COVID-19 Pandemic

State Operations Manual. Appendix PP -Guidance to Surveyors For Long Term Care 106 Facilities

Emergency Department Summary Tables

Pharmacotherapy for hospitalized 117 patients with COVID-19: treatment patterns by disease severity

Polypharmacy among COVID-19 patients: A 120 systematic review

J o u r n a l P r e -p r o o f